Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ADCT NASDAQ:AQST NASDAQ:OCGN NASDAQ:TLRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$1.21+1.3%$2.44$0.78▼$4.98$153.26M1.871.32 million shs296,555 shsAQSTAquestive Therapeutics$4.24+1.3%$4.22$2.93▼$7.55$531.37M1.453.17 million shs616,297 shsOCGNOcugen$1.50-1.0%$1.41$0.91▼$2.73$506.09M2.187.87 million shs2.99 million shsTLRYTilray Brands$4.42-4.4%$5.29$4.28▼$23.20$512.24M1.894.27 million shs2.83 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics0.00%+16.43%+17.56%-67.21%-56.81%AQSTAquestive Therapeutics0.00%-4.78%+6.36%+2.20%+12.37%OCGNOcugen0.00%+0.67%+17.97%-14.69%+56.31%TLRYTilray Brands0.00%-0.43%-6.48%-30.63%-12.99%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$1.21+1.3%$2.44$0.78▼$4.98$153.26M1.871.32 million shs296,555 shsAQSTAquestive Therapeutics$4.24+1.3%$4.22$2.93▼$7.55$531.37M1.453.17 million shs616,297 shsOCGNOcugen$1.50-1.0%$1.41$0.91▼$2.73$506.09M2.187.87 million shs2.99 million shsTLRYTilray Brands$4.42-4.4%$5.29$4.28▼$23.20$512.24M1.894.27 million shs2.83 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics0.00%+16.43%+17.56%-67.21%-56.81%AQSTAquestive Therapeutics0.00%-4.78%+6.36%+2.20%+12.37%OCGNOcugen0.00%+0.67%+17.97%-14.69%+56.31%TLRYTilray Brands0.00%-0.43%-6.48%-30.63%-12.99%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADCTADC Therapeutics 2.33Hold$6.25418.67% UpsideAQSTAquestive Therapeutics 3.00Buy$8.50100.71% UpsideOCGNOcugen 2.60Moderate Buy$9.50535.45% UpsideTLRYTilray Brands 2.25Hold$11.50160.48% UpsideCurrent Analyst Ratings BreakdownLatest ADCT, OCGN, AQST, and TLRY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2026OCGNOcugen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/8/2026ADCTADC Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral6/4/2026ADCTADC Therapeutics StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$5.006/4/2026ADCTADC Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight6/4/2026ADCTADC Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Sector Perform$6.00 ➝ $2.006/2/2026OCGNOcugen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/27/2026OCGNOcugen Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $11.005/18/2026OCGNOcugen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/13/2026TLRYTilray Brands Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/5/2026ADCTADC Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$6.005/5/2026ADCTADC Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.00(Data available from 7/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADCTADC Therapeutics$81.36M1.88N/AN/A($1.50) per share-0.80AQSTAquestive Therapeutics$44.54M11.93N/AN/A($0.28) per share-15.13OCGNOcugen$4.47M113.35N/AN/A($0.04) per share-37.38TLRYTilray Brands$821.31M0.63$1.38 per share3.20$14.04 per share0.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADCTADC Therapeutics-$142.62M-$1.05N/AN/AN/A-173.02%N/A-44.70%8/11/2026 (Estimated)AQSTAquestive Therapeutics-$83.78M-$0.61N/AN/AN/A-137.08%N/A-49.33%8/10/2026 (Estimated)OCGNOcugen-$67.85M-$0.24N/AN/AN/AN/A-127,987.80%-135.48%7/30/2026 (Estimated)TLRYTilray Brands-$2.19B-$13.65N/AN/AN/A-156.51%-3.31%-2.42%7/27/2026 (Estimated)Latest ADCT, OCGN, AQST, and TLRY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2026Q2 2026OCGNOcugen-$0.05N/AN/AN/A$0.98 millionN/A7/27/2026Q4 2026TLRYTilray Brands-$0.01N/AN/AN/A$251.11 millionN/A5/13/2026Q1 2026AQSTAquestive Therapeutics-$0.14-$0.07+$0.07-$0.07$10.90 million$14.45 million5/5/2026Q1 2026OCGNOcugen-$0.05-$0.06-$0.01-$0.06$0.42 million$1.53 million5/4/2026Q1 2026ADCTADC Therapeutics-$0.19-$0.21-$0.02-$0.21$19.99 million$20.85 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADCTADC TherapeuticsN/AN/AN/AN/AN/AAQSTAquestive TherapeuticsN/AN/AN/AN/AN/AOCGNOcugenN/AN/AN/AN/AN/ATLRYTilray BrandsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADCTADC TherapeuticsN/A4.094.02AQSTAquestive TherapeuticsN/A4.103.85OCGNOcugen4.171.861.86TLRYTilray Brands0.192.791.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADCTADC Therapeutics41.10%AQSTAquestive Therapeutics32.45%OCGNOcugen10.27%TLRYTilray Brands9.35%Insider OwnershipCompanyInsider OwnershipADCTADC Therapeutics5.40%AQSTAquestive Therapeutics6.81%OCGNOcugen3.95%TLRYTilray Brands0.84%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADCTADC Therapeutics310127.19 million120.32 millionOptionableAQSTAquestive Therapeutics160125.47 million116.92 millionOptionableOCGNOcugen80338.52 million325.15 millionOptionableTLRYTilray Brands2,842116.55 million115.57 millionOptionableADCT, OCGN, AQST, and TLRY HeadlinesRecent News About These CompaniesTop Canadian Marijuana Stock Picks For Investors Today27 minutes ago | marijuanastocks.comMCould Tilray Brands (NASDAQ:TLRY) Benefit From Medical Cannabis Growth?July 6 at 6:58 AM | kalkinemedia.comKWhat Does Tilray Brands (TLRY) Gain From The HelloMD Corporation Acquisition?July 5 at 10:48 PM | finance.yahoo.comCannabis Stocks To Keep An Eye On - July 4thJuly 5 at 4:01 AM | americanbankingnews.comBest Cannabis Stocks To Follow Now - July 3rdJuly 4 at 4:39 AM | americanbankingnews.comPromising Cannabis Stocks To Research - July 2ndJuly 3 at 4:09 AM | americanbankingnews.comIs Tilray a Textbook Value Trap -- or the Most Undervalued Cannabis Stock on the Market?July 2, 2026 | fool.comTLRY Plans Strategic Medical Cannabis Expansion: Time to Buy or Sell?July 2, 2026 | zacks.comA Revolutionary Technology Narrative Has Surged—Don't Take the BaitJuly 2, 2026 | 247wallst.comPromising Cannabis Stocks To Watch Today - July 1stJuly 2, 2026 | americanbankingnews.comTilray Brands, Inc. (TLRY) Suffers a Larger Drop Than the General Market: Key InsightsJuly 1, 2026 | finance.yahoo.comTilray Brands, Inc. (TLRY) Suffers a Larger Drop Than the General Market: Key InsightsJuly 1, 2026 | zacks.comBrewDog CEO exits in wake of Tilray takeoverJuly 1, 2026 | just-drinks.comJTop Cannabis Stocks To Follow Now - June 30thJuly 1, 2026 | americanbankingnews.comBreckenridge Distillery Earns Double Gold for Rum Cask Finish at New York International Spirits CompetitionJune 30, 2026 | finance.yahoo.comTilray Brands (NASDAQ:TLRY) Trading Down 2.6% - Here's What HappenedJune 30, 2026 | marketbeat.comTilray conducts debt-for-equity exchange to boost financesJune 30, 2026 | tipranks.comBreckenridge Distillery Earns Double Gold for Rum Cask Finish at New York International Spirits CompetitionJune 30, 2026 | financialpost.comFCannabis's 280E Tax Trap May Finally Break. We've Heard That Before.June 30, 2026 | 247wallst.comTilray Beer Brands SweetWater, 10 Barrel, Breckenridge, BrewDog, Montauk, Blue Point, Hop Valley and Terrapin Tap into America's 250th with Fourth of July Celebrations NationwideJune 30, 2026 | globenewswire.comPromising Cannabis Stocks To Watch Today - June 29thJune 30, 2026 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADCT, OCGN, AQST, and TLRY Company DescriptionsADC Therapeutics NYSE:ADCT$1.20 +0.02 (+1.26%) As of 01:09 PM Eastern This is a fair market value price provided by Massive. Learn more.ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.Aquestive Therapeutics NASDAQ:AQST$4.24 +0.06 (+1.32%) As of 01:08 PM Eastern This is a fair market value price provided by Massive. Learn more.Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.Ocugen NASDAQ:OCGN$1.50 -0.02 (-0.99%) As of 01:09 PM Eastern This is a fair market value price provided by Massive. Learn more.Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.Tilray Brands NASDAQ:TLRY$4.42 -0.21 (-4.44%) As of 01:09 PM Eastern This is a fair market value price provided by Massive. Learn more.Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street AI Is Selling Off, But These 5 Stocks Could Benefit Next MarketBeat Week in Review – 06/29 - 07/03 Analysts Just Raised Price Targets On These 3 Semiconductor Equipment Stocks Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst This Under-the-Radar Industrial Is Quietly Powering AI Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
